


HEALTHCARE

The Pharmaceutical Licensing Outlook

A strategic guide to effective deal-making and profitable partnerships

By Steven Seget

 [Table of Contents](#)

Steven Seget

Steven Seget is the Director of Delphi Pharma, and provides independent strategic consulting services to the pharmaceutical and biotechnology industries. Steven previously managed the strategic healthcare consulting function at Datamonitor and graduated from the London School of Economics in Accounting & Finance. **Error! Hyperlink reference not valid.**

Delphi Pharma provides strategic, financial and market-based solutions to clients, focusing primarily on the business development and licensing functions. Delphi Pharma combines an extensive research network, applied analytical expertise and an established track record to deliver high value results and measurable impact to its clients. **Error! Hyperlink reference not valid.**

Copyright © 2002 Business Insights Ltd

This Management Report is published by Business Insights Ltd. All rights reserved. Reproduction or redistribution of this Management Report in any form for any purpose is expressly prohibited without the prior consent of Business Insights Ltd.

The views expressed in this Management Report are those of the publisher, not of Business Insights. Business Insights Ltd accepts no liability for the accuracy or completeness of the information, advice or comment contained in this Management Report nor for any actions taken in reliance thereon.

While information, advice or comment is believed to be correct at the time of publication, no responsibility can be accepted by Business Insights Ltd for its completeness or accuracy.

Printed and bound in Great Britain by MBA Group Limited, MBA House, Garman Road, London N17 0HW. www.mba-group.com

Table of Contents

The Pharmaceutical Licensing Outlook *A strategic guide to effective deal-making and profitable partnerships*

Executive Summary	10
The Licensing Era	10
Licensing Trends	11
Implementing Strategic Objectives	12
Sophisticated Deal-Making	13
Creating Effective Partnerships	14
Licensing Strategy	15
Chapter 1 The Licensing Era	18
Summary	18
Introduction	19
Industry trends	19
Structural changes to the value chain	20
Biotechnology	20
Drug delivery	23
Genomics	26
M&A activity	29
Globalization	31
A widening expectations gap	34
Partnership and collaboration	37
Key drivers of licensing activity for integrated pharmaceutical companies	40
Plugging the R&D productivity gap	40
Accessing new technologies and expertise	41
Building critical mass	42
Key drivers of licensing activity for specialist technology companies	42
Generating financial returns	43
Accessing development and marketing experience	43
Building critical mass	45

Chapter 2 Licensing Trends 48

Summary	48
Introduction	49
The impact of licensing	49
Growth in licensing activity	49
Key licensing trends	53
Value and importance of licensing	53
Competition for partnering	56
Results of licensing	59
Earned licensing revenues	59
Product launches through licensing	61
Marketed licensed products	63
The evolution of strategic licensing	66
Traditional licensing	67
Leading licensing agreements	68
Eli Lilly/Genentech (Humulin) – 1978	68
Kirin/Amgen (erythropoietin) – 1984	69
Glaxo/BioChem (3TC) – 1990	70
Allergan/Ligand (retinoid compounds) – 1992	71
Lilly/Centocor (Centoxin/ReoPro) – 1992	72
SmithKline/Human Genome Sciences (gene sequencing) – 1993	73
Bayer/Millennium (genomic small molecules) – 1998	73
Innovex/CV Therapeutics (Ranolazine) – 1999	74
Novartis/Vertex Pharmaceuticals (Kinase targeted drugs) – 2000	74
Eli Lilly/ISIS (ISIS-3521/metabolic & inflammatory diseases) – 2001	75
Licensing as a strategic tool	75
Key future trends in licensing	77
Implementing strategic objectives	78
Sophisticated deal-making	78
Creating effective partnerships	79

Chapter 3 Implementing Strategic Objectives 82

Summary	82
Introduction	83
Linking licensing to corporate strategy	83
Accessing new discovery expertise	84
Building new therapeutic franchises	85
Creating critical mass to launch a new drug	85
Establishing new development and marketing expertise	86
Generating financial funding	87
Licensing agreement case studies	88

Novartis/Vertex Pharmaceuticals	88
Genentech/OSI/Roche	91
Abbott/Millennium	93
Roche Diagnostics/deCODE Genetics	95
Eli Lilly/ISIS Pharmaceuticals	97
Critical success factors	99
Licensing as a strategic tool	100
Choosing the most appropriate tool	100
Matching strategic objectives	100
Extending strategic objectives	101
Generating additional strategic opportunities	101

Chapter 4 Sophisticated Deal-Making 104

Summary	104
Introduction	105
Optimizing returns through complex deal terms	105
The deal-making process	106
Deal structure and terms	107
Complex deal financing	109
Measurement frameworks	111
Traditional net present value	112
Monte Carlo simulation	116
Real options	119
Adjusted present value	124
Contract theory	125
Critical success factors	127
Comprehensive due diligence	127
Structuring risks, responsibilities and rewards	128
Financing to spare P&L earnings	129
Measuring risks and contingencies	129
Evaluating contract dynamics	129

Chapter 5 Creating Effective Partnerships 132

Summary	132
Introduction	133
The deal-making organization	133
Deliberate licensing	133
Licensing as an organization	134
Becoming a partner of choice	135
The partnering organization	136
Partnership management	137
Internal and external relationships	138

Key procedures and interventions	139
Management commitment	140
Objectives, priorities and responsibilities	141
Communication channels	141
Collaborative decision making	141
Resolving conflict	141
Progress and results	142
Critical success factors	142
Coordinated licensing strategy	143
Desirable licensing partner	143
Internal and external alliances	143
Structures and procedures	144
Relationship management skills	144

Chapter 6 Licensing Strategy 148

Summary	148
Introduction	149
Competing through licensing	149
Implementing strategic objectives	149
Sophisticated deal-making	150
Creating effective partnerships	151
Company case studies	152
Pfizer	152
Licensing strategy	152
Key agreements	153
Recent licensing activity	155
Novartis	162
Licensing strategy	162
Key agreements	164
Recent licensing activity	165
Takeda	172
Licensing strategy	173
Key agreements	173
Recent licensing activity	175
Genentech	176
Licensing strategy	176
Key agreements	177
Recent licensing activity	179
Millennium	183
Licensing strategy	183
Key agreements	184
Recent licensing activity	185
Effective licensing strategy	192
Blockbuster	192
Innovation	193
Geographical	194

Consolidation	194
Expansion	195

Chapter 7 Appendix 198

Glossary	198
Sources list	202
Index	208

List of Figures

Figure 1.1:	Biotechnology vs. non-biotechnology product launches, 1991—2000	22
Figure 1.2:	Total global sales by drug delivery technology, 1997—1999	24
Figure 1.3:	Aventis SA's recent M&A history, 1990—2000	30
Figure 1.4:	Global retail sales, 2000—2001	32
Figure 1.5:	R&D productivity levels, 1980—2001	36
Figure 1.6:	Forecast R&D productivity levels, 2000—2050	37
Figure 1.7:	The licensing era – partnership and collaboration	38
Figure 2.8:	Trends in pharmaceutical alliances, 1996—2000	51
Figure 2.9:	Trends in biotechnology alliances, 1996—2000	52
Figure 2.10:	Licensing agreements by development phase, July 2000—June 2001	57
Figure 2.11:	Genomics-related licensing trends, 1997—2000	58
Figure 2.12:	Licensing revenues earned by leading 100 biotechnology companies, 1997—2001	60
Figure 2.13:	Average licensing payments made by top 20 pharmaceutical companies, 1988—2000	61
Figure 2.14:	Joint development and licensing for NME launches, 1998—2000	62
Figure 2.15:	Leading licensed drugs, 1998—2000	65
Figure 3.16:	Novartis/Vertex Pharmaceuticals, May 2000	90
Figure 3.17:	Genentech/OSI/Roche, January 2001	92
Figure 3.18:	Abbott/Millennium, March 2001	94
Figure 3.19:	Roche Diagnostics/deCODE Genetics, June 2001	96
Figure 3.20:	Eli Lilly/ISIS Pharmaceuticals, August 2001	98
Figure 4.21:	Licensing case study – NPV evaluation	114
Figure 4.22:	Licensing case study – ENPV evaluation	116
Figure 4.23:	Licensing case study – Monte Carlo simulation	118
Figure 4.24:	Licensing case study – Real options	121
Figure 4.25:	Overview of the adjusted present value framework	125
Figure 5.26:	Internal and external partnership relationships	139

List of Tables

Table 1.1:	Biotechnology vs. non-biotechnology product launches, 1991—2000	21
Table 1.2:	Total global sales by drug delivery technology, 1997—1999	24
Table 1.3:	Summary results of major genomics collaborations, 2001	28
Table 1.4:	Global retail sales, 2000—2001	32
Table 1.5:	R&D productivity levels, 1980—2001	36
Table 2.6:	Trends in pharmaceutical alliances, 1996—2000	51
Table 2.7:	Trends in biotechnology alliances, 1996—2000	52
Table 2.8:	Average licensing deal values, 2000	54
Table 2.9:	Licensing revenues earned by leading 100 biotechnology companies, 1997—2001	60
Table 2.10:	Average licensing payments made by top 20 pharmaceutical companies, 1988—2000	61
Table 2.11:	Joint development and licensing for NME launches, 1998—2000	62
Table 2.12:	Leading licensed drugs, 1998—2000	64
Table 2.13:	Leading licensed drugs, 2000	66
Table 2.14:	Leading licensing agreements, 1978—2001	68
Table 6.15:	Novartis's key R&D collaborators, 2001	163